Headlines about Aimmune Therapeutics (NASDAQ:AIMT) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aimmune Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5899830102866 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
A number of analysts have recently weighed in on AIMT shares. Credit Suisse Group set a $45.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, January 11th. Roth Capital increased their target price on shares of Aimmune Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Deutsche Bank set a $30.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 20th. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Royal Bank of Canada started coverage on shares of Aimmune Therapeutics in a report on Wednesday, February 7th. They issued an “outperform” rating and a $55.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $57.22.
Shares of Aimmune Therapeutics (AIMT) opened at $31.65 on Friday. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $42.00. The company has a market cap of $1,827.88, a PE ratio of -12.13 and a beta of -0.49.
In other news, insider Douglas T. Sheehy sold 1,648 shares of Aimmune Therapeutics stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $37.33, for a total transaction of $61,519.84. Following the completion of the transaction, the insider now directly owns 1,648 shares in the company, valued at $61,519.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathryn E. Falberg bought 30,000 shares of the stock in a transaction dated Monday, February 26th. The shares were acquired at an average price of $32.00 per share, with a total value of $960,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 58,093 shares of company stock valued at $1,858,976 and sold 133,968 shares valued at $5,073,180. Company insiders own 24.56% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Aimmune Therapeutics (AIMT) Share Price” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/18/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-aimmune-therapeutics-aimt-share-price.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.